cml
No description yet: the sentence for this tag has not been written. 3 records carry it: 2 biomarkers, 1 person.
By kind
3 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
BCR::ABL1 T315I BCR-ABL1 T315I is the gatekeeper mutation in the ABL1 kinase that defeats imatinib, dasatinib, nilotinib and bosutinib. Ponatinib and asciminib are the two drugs approved for it. | Chronic myeloid leukaemia, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia, accelerated and blast phase | none | biomarker, resistance | ||
BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR) BCR-ABL1 The BCR::ABL1 fusion is the Philadelphia chromosome that defines chronic myeloid leukaemia and some acute lymphoblastic leukaemia. Its transcript level in blood, on the international scale, is how response to tyrosine kinase inhibitors is measured and when treatment can be stopped. | Chronic myeloid leukaemia, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia, accelerated and blast phase | none | biomarker | ||
Timothy P. Hughes Consultant Haematologist, Royal Adelaide Hospital; Cancer Theme Leader, South Australian Health and Medical Research Institute · Royal Adelaide Hospital Defined molecular response monitoring in CML and showed that many patients can safely stop imatinib. | Chronic myeloid leukaemia | none | molecular-monitoring, australia |
